Table 1.
Demographics and clinical characteristics.
| Patients (N = 159) | p | ||||
|---|---|---|---|---|---|
| CRT (n = 125) |
BRT (n = 34) |
||||
| # | % | # | % | ||
| Age at diagnosis, years | 0.01 | ||||
| Median | 58 | 63 | |||
| Range | 35–80 | 44–81 | |||
| Gender | 0.78 | ||||
| Male | 108 | 86.4 | 30 | 88.2 | |
| Female | 17 | 13.6 | 4 | 11.8 | |
| Race | 0.01 | ||||
| White | 114 | 91.2 | 25 | 73.5 | |
| Non-white | 11 | 8.8 | 9 | 26.5 | |
| KPS | 0.02 | ||||
| ≥90 | 92 | 78.0 | 19 | 57.6 | |
| <90 | 26 | 22.0 | 14 | 42.4 | |
| T-classification | 0.22 | ||||
| T1–T2 | 77 | 61.6 | 17 | 50.0 | |
| T3–T4 | 48 | 38.4 | 17 | 50.0 | |
| N-classification | <0.01 | ||||
| N0-1 | 27 | 21.6 | 19 | 55.9 | |
| N2-3 | 98 | 78.4 | 15 | 44.1 | |
| Tobacco use | 0.02 | ||||
| ≤10 pack-years | 48 | 38.4 | 6 | 17.6 | |
| >10 pack-years | 77 | 61.6 | 28 | 82.4 | |
| HPV status | 0.01 | ||||
| Negative | 23 | 18.4 | 14 | 41.2 | |
| Positive | 71 | 56.8 | 12 | 35.3 | |
| Unknown | 31 | 24.8 | 8 | 23.5 | |
| Site | 0.08 | ||||
| Oropharynx | 93 | 74.4 | 20 | 58.8 | |
| Larynx | 32 | 25.6 | 14 | 41.2 | |
| Radiation dose | 0.43 | ||||
| <69.3 Gy | 32 | 25.6 | 11 | 32.4 | |
| ≥69.3 Gy | 93 | 74.4 | 23 | 67.6 | |
| Radiation interruption | 0.86 | ||||
| <10 days | 122 | 97.6 | 33 | 97.5 | |
| ≥10 days | 3 | 2.4 | 1 | 2.5 | |
| Overall survival, months | 0.04 | ||||
| Median | 97.9 | 58.1 | |||
| 95%CI | 62.9–117.1 | 18.1–97.9 | |||
Abbreviations: CRT, chemoradiotherapy; BRT, bioradiotherapy; KPS, Karnofsky performance status; HPV, human papillomavirus; Gy, gray; 95%CI, 95% confidence interval.